Breakthrough T1D, Formerly JDRF, Celebrates Progress in Cell Therapy Research on the Path to Type 1 Diabetes Cures as Vertex Announces Pivotal Trial for VX-880
November 04, 2024
November 04, 2024
NEW YORK, Nov. 4 -- Breakthrough T1D (formerly JDRF) a non-profit dedicated to funding type 1 diabetes research, issued the following news release:
An announcement today by Vertex demonstrates progress on the path to type 1 diabetes (T1D) cures with the conversion of their current clinical trial for VX-880 to include phase 3. The pivotal trial will evaluate the safety and efficacy of the therapy.
"Breakthrough T1D is thrilled that Vertex has committed to the first . . .
An announcement today by Vertex demonstrates progress on the path to type 1 diabetes (T1D) cures with the conversion of their current clinical trial for VX-880 to include phase 3. The pivotal trial will evaluate the safety and efficacy of the therapy.
"Breakthrough T1D is thrilled that Vertex has committed to the first . . .